BR112017025297A2 - anticorpos anti-gitr para diagnóstico do câncer - Google Patents

anticorpos anti-gitr para diagnóstico do câncer

Info

Publication number
BR112017025297A2
BR112017025297A2 BR112017025297-0A BR112017025297A BR112017025297A2 BR 112017025297 A2 BR112017025297 A2 BR 112017025297A2 BR 112017025297 A BR112017025297 A BR 112017025297A BR 112017025297 A2 BR112017025297 A2 BR 112017025297A2
Authority
BR
Brazil
Prior art keywords
gitr
cancer diagnosis
gitr antibodies
antibodies
immunotherapy
Prior art date
Application number
BR112017025297-0A
Other languages
English (en)
Inventor
Wang Xi-Tao
A. ADELAKUN Olufemi
C. LEWIN Anne
J. Korman Alan
J. Selby Mark
Wang Changyu
Huang Haichun
A. Henning Karla
Lonberg Nils
Srinivasan Mohan
Minhua Han Michelle
Chen Guodong
Huang Richard
Chakraborty Indrani
Chien-Szu Wong Susan
Li Huiming
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of BR112017025297A2 publication Critical patent/BR112017025297A2/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/7051—T-cell receptor (TcR)-CD3 complex
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30 CD40 or CD95
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
    • G01N2333/7151—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF]; for lymphotoxin [LT]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7023—(Hyper)proliferation
    • G01N2800/7028—Cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

a presente invenção refere-se a anticorpos diagnósticos que se ligam ao receptor do fator de necrose tumoral induzido por glicocorticoides (gitr). tais anticorpos são úteis para os métodos de detectar a expressão do gitr em amostras biológicas, por exemplo, o tecido de tumor, e identificar um paciente com câncer propenso a responder à imunoterapia anti-gitr ou predizer se um paciente com câncer responderá à imunoterapia anti-gitr.
BR112017025297-0A 2015-06-03 2016-06-02 anticorpos anti-gitr para diagnóstico do câncer BR112017025297A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562170579P 2015-06-03 2015-06-03
US62/170,579 2015-06-03
PCT/US2016/035514 WO2016196792A1 (en) 2015-06-03 2016-06-02 Anti-gitr antibodies for cancer diagnostics

Publications (1)

Publication Number Publication Date
BR112017025297A2 true BR112017025297A2 (pt) 2018-08-14

Family

ID=56194564

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017025297-0A BR112017025297A2 (pt) 2015-06-03 2016-06-02 anticorpos anti-gitr para diagnóstico do câncer

Country Status (10)

Country Link
US (2) US10690674B2 (pt)
EP (1) EP3304079B1 (pt)
JP (1) JP6812364B2 (pt)
CN (1) CN107743586B (pt)
BR (1) BR112017025297A2 (pt)
CA (1) CA2988115A1 (pt)
EA (1) EA201792497A1 (pt)
ES (1) ES2810856T3 (pt)
MX (1) MX2017015260A (pt)
WO (1) WO2016196792A1 (pt)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE047385T2 (hu) 2014-06-06 2020-04-28 Bristol Myers Squibb Co Antitestek glükokortikoid indukált tumornekrózis faktor receptor (GITR) ellen és annak felhasználásai
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
WO2016196792A1 (en) 2015-06-03 2016-12-08 Bristol-Myers Squibb Company Anti-gitr antibodies for cancer diagnostics
CA2992298A1 (en) 2015-07-23 2017-01-26 Inhibrx Lp Multivalent and multispecific gitr-binding fusion proteins
WO2017068186A1 (en) * 2015-10-22 2017-04-27 Ablynx Nv Gitr agonists
US10281374B2 (en) * 2015-11-04 2019-05-07 Diagnostic Biosystems Method of pretreatment of biological samples for an analyte-staining assay method
WO2017087678A2 (en) * 2015-11-19 2017-05-26 Bristol-Myers Squibb Company Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof
RU2756236C2 (ru) 2016-06-20 2021-09-28 Кимаб Лимитед PD-L1 специфические антитела
CA3054885A1 (en) * 2017-03-03 2018-09-07 Rinat Neuroscience Corp. Anti-gitr antibodies and methods of use thereof
WO2018185618A1 (en) 2017-04-03 2018-10-11 Novartis Ag Anti-cdh6 antibody drug conjugates and anti-gitr antibody combinations and methods of treatment
BR112019021680A2 (pt) 2017-04-20 2020-05-12 Adc Therapeutics Sa Terapia de combinação com conjugado anticorpo-fármaco anti-cd25??
EP3612234B1 (en) 2017-04-20 2024-03-13 ADC Therapeutics SA Combination therapy with an anti-axl antibody-drug conjugate
AR111651A1 (es) 2017-04-28 2019-08-07 Novartis Ag Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación
JP7274426B2 (ja) 2017-05-16 2023-05-16 ブリストル－マイヤーズ スクイブ カンパニー 抗ｇｉｔｒアゴニスト抗体での癌の処置
UA127900C2 (uk) 2017-06-14 2024-02-07 Ейдісі Терапьютікс Са Схема дозування для введення adc до cd19
WO2018229715A1 (en) 2017-06-16 2018-12-20 Novartis Ag Compositions comprising anti-cd32b antibodies and methods of use thereof
CN110785187B (zh) 2017-06-22 2024-04-05 诺华股份有限公司 针对cd73的抗体分子及其用途
JP2020524694A (ja) 2017-06-22 2020-08-20 ノバルティス アーゲー がんの処置における使用のためのＩＬ−１β結合性抗体
WO2018235056A1 (en) 2017-06-22 2018-12-27 Novartis Ag IL-1BETA BINDING ANTIBODIES FOR USE IN THE TREATMENT OF CANCER
WO2018237173A1 (en) 2017-06-22 2018-12-27 Novartis Ag ANTIBODY MOLECULES DIRECTED AGAINST CD73 AND CORRESPONDING USES
US20200223924A1 (en) 2017-06-27 2020-07-16 Novartis Ag Dosage regimens for anti-tim-3 antibodies and uses thereof
JP2020527572A (ja) 2017-07-20 2020-09-10 ノバルティス アーゲー 抗ｌａｇ−３抗体の投薬量レジメンおよびその使用
US11596694B2 (en) * 2017-09-20 2023-03-07 Mersana Therapeutics, Inc. Compositions and methods for predicting response to NaPi2b-targeted therapy
US20210040205A1 (en) 2017-10-25 2021-02-11 Novartis Ag Antibodies targeting cd32b and methods of use thereof
BR112020008888A2 (pt) 2017-11-16 2020-10-20 Novartis Ag terapias de combinação
CN110357958A (zh) 2018-03-26 2019-10-22 信达生物制药(苏州)有限公司 抗糖皮质激素诱导的肿瘤坏死因子受体(gitr)的小型化抗体、其聚合物及应用
US20210147547A1 (en) 2018-04-13 2021-05-20 Novartis Ag Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof
MX2020012418A (es) 2018-05-23 2021-04-28 Adc Therapeutics Sa Adyuvante molecular.
US20210214459A1 (en) 2018-05-31 2021-07-15 Novartis Ag Antibody molecules to cd73 and uses thereof
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
US11192877B2 (en) 2018-07-10 2021-12-07 Novartis Ag 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
WO2020021465A1 (en) 2018-07-25 2020-01-30 Advanced Accelerator Applications (Italy) S.R.L. Method of treatment of neuroendocrine tumors
WO2020089811A1 (en) 2018-10-31 2020-05-07 Novartis Ag Dc-sign antibody drug conjugates
WO2020128972A1 (en) 2018-12-20 2020-06-25 Novartis Ag Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
WO2020128637A1 (en) 2018-12-21 2020-06-25 Novartis Ag Use of il-1 binding antibodies in the treatment of a msi-h cancer
WO2020128613A1 (en) 2018-12-21 2020-06-25 Novartis Ag Use of il-1beta binding antibodies
US20200369762A1 (en) 2018-12-21 2020-11-26 Novartis Ag Use of il-1beta binding antibodies
CN113227138A (zh) 2018-12-21 2021-08-06 诺华股份有限公司 IL-1β结合抗体的用途
US20220144807A1 (en) 2019-02-15 2022-05-12 Novartis Ag 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
CN113329792A (zh) 2019-02-15 2021-08-31 诺华股份有限公司 取代的3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途
BR112022007376A2 (pt) 2019-10-21 2022-07-05 Novartis Ag Terapias de combinação com venetoclax e inibidores de tim-3
TW202128191A (zh) 2019-10-21 2021-08-01 瑞士商諾華公司 Tim-3抑制劑及其用途
GB201917254D0 (en) 2019-11-27 2020-01-08 Adc Therapeutics Sa Combination therapy
US20230056470A1 (en) 2019-12-20 2023-02-23 Novartis Ag Uses of anti-tgf-beta antibodies and checkpoint inhibitors for the treatment of proliferative diseases
CN114980902A (zh) 2020-01-17 2022-08-30 诺华股份有限公司 用于治疗骨髓增生异常综合征或慢性粒单核细胞白血病的包含tim-3抑制剂和低甲基化药物的组合
CN116096862A (zh) 2020-06-11 2023-05-09 诺华股份有限公司 Zbtb32抑制剂及其用途
WO2021260528A1 (en) 2020-06-23 2021-12-30 Novartis Ag Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
EP4188549A1 (en) 2020-08-03 2023-06-07 Novartis AG Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
EP4204020A1 (en) 2020-08-31 2023-07-05 Advanced Accelerator Applications International S.A. Method of treating psma-expressing cancers
EP4204021A1 (en) 2020-08-31 2023-07-05 Advanced Accelerator Applications International S.A. Method of treating psma-expressing cancers
GB202102396D0 (en) 2021-02-19 2021-04-07 Adc Therapeutics Sa Molecular adjuvant
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
AR125874A1 (es) 2021-05-18 2023-08-23 Novartis Ag Terapias de combinación
WO2023178192A1 (en) 2022-03-15 2023-09-21 Compugen Ltd. Il-18bp antagonist antibodies and their use in monotherapy and combination therapy in the treatment of cancer

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
US7247302B1 (en) 1996-08-02 2007-07-24 Bristol-Myers Squibb Company Method for inhibiting immunoglobulin-induced toxicity resulting from the use of immunoglobulins in therapy and in vivo diagnosis
DE69738749D1 (de) 1996-08-16 2008-07-17 Schering Corp Zelloberflächen-antigen aus säugetieren und verwandte reagenzien
US6111090A (en) 1996-08-16 2000-08-29 Schering Corporation Mammalian cell surface antigens; related reagents
WO2001040464A1 (en) 1999-11-30 2001-06-07 Genentech, Inc. Interleukin-1-receptor associated kinase-3 (irak3) and its use in promotion or inhibition of angiogenesis and cardiovascularization
GB9625074D0 (en) 1996-12-02 1997-01-22 Pharmacia & Upjohn Spa Receptor belonging to the TNF/NGF receptor family
WO2000032778A2 (en) 1998-12-01 2000-06-08 Genentech, Inc. Methods and compositions for inhibiting neoplastic cell growth
AU1102399A (en) 1997-10-21 1999-05-10 Human Genome Sciences, Inc. Human tumor necrosis factor receptor-like proteins tr11, tr11sv1, and tr11sv2
AU760010B2 (en) 1997-11-18 2003-05-08 Genentech Inc. DNA19355 polypeptide, a tumor necrosis factor homolog
CA2319236A1 (en) 1998-02-09 1999-08-12 Genentech, Inc. Novel tumor necrosis factor receptor homolog and nucleic acids encoding the same
CA2335653A1 (en) 1998-07-22 2000-02-03 Incyte Pharmaceuticals, Inc. Molecules associated with cell proliferation
KR100529270B1 (ko) 1998-12-01 2005-11-21 제넨테크, 인크. 혈관신생 및 심혈관형성의 촉진 또는 억제
AU3860100A (en) 1999-02-24 2000-09-14 Human Genome Sciences, Inc. Human tumor necrosis factor receptor-like proteins tr11, tr11sv1, and tr11sv2
DK1196186T3 (da) 1999-07-12 2008-03-03 Genentech Inc Stimulering eller inhibering af angiogenese og kardiovaskularisation med tumornekrosefaktorligand/receptorhomologer
CA2395539C (en) 1999-12-23 2009-08-25 Zymogenetics, Inc. Soluble interleukin-20 receptor
EP2295079A3 (en) 1999-12-23 2011-03-23 ZymoGenetics, L.L.C. Method for treating inflammation
AU2001249727A1 (en) 2000-03-31 2001-10-15 Genentech, Inc. Compositions and methods for detecting and quantifying gene expression
AU2001274888A1 (en) 2000-05-19 2001-12-03 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
EP1351703B1 (en) 2000-09-15 2006-07-26 ZymoGenetics, Inc. Use of a polypeptide comprising the extracellular domains of il-20ra and il-20rb for the treatment of inflammation
WO2002072607A2 (en) 2001-03-09 2002-09-19 Zymogenetics, Inc. Soluble heterodimeric cytokine receptor
US20030133936A1 (en) 2001-07-12 2003-07-17 Byrne Michael Chapman CD25markers and uses thereof
AUPS054702A0 (en) 2002-02-14 2002-03-07 Immunaid Pty Ltd Cancer therapy
EP2116616A3 (en) 2002-09-11 2010-03-17 Genentech, Inc. Genes differentially expressed in activated T cells and uses thereof
EP2322201A3 (en) 2002-10-29 2011-07-27 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
AU2003302386B2 (en) 2002-11-26 2010-04-01 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
RU2369636C2 (ru) 2003-05-23 2009-10-10 Уайт Лиганд gitr и связанные с лигандом gitr молекулы и антитела и варианты их применения
US20050048054A1 (en) 2003-07-11 2005-03-03 Shino Hanabuchi Lymphocytes; methods
GB0407315D0 (en) 2003-07-15 2004-05-05 Cambridge Antibody Tech Human antibody molecules
WO2005019258A2 (en) 2003-08-11 2005-03-03 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
JP2007537993A (ja) 2003-11-21 2007-12-27 ザイモジェネティクス， インコーポレイテッド 抗ｉｌ−２０受容体抗体および結合パートナーならびに炎症において用いる方法
DK1737891T3 (da) 2004-04-13 2013-03-25 Hoffmann La Roche Anti-p-selectin-antistoffer
WO2006050172A2 (en) 2004-10-29 2006-05-11 University Of Southern California Combination cancer immunotherapy with co-stimulatory molecules
US20060099171A1 (en) 2004-11-05 2006-05-11 Masahide Tone Mouse glucocorticoid-induced TNF receptor ligand is costimulatory for T cells
JP2008527998A (ja) * 2005-01-19 2008-07-31 ジェンザイム・コーポレイション Ｎｓｃｌｃの診断のためのｇｉｔｒ抗体
WO2006105021A2 (en) * 2005-03-25 2006-10-05 Tolerrx, Inc. Gitr binding molecules and uses therefor
WO2006124269A2 (en) 2005-05-16 2006-11-23 Amgen Fremont Inc. Human monoclonal antibodies that bind to very late antigen-1 for the treatment of inflammation and other disorders
WO2006132272A1 (ja) 2005-06-07 2006-12-14 The University Of Tokyo 抗体の作製方法
EP1899379B1 (en) 2005-06-20 2018-04-11 E. R. Squibb & Sons, L.L.C. Cd19 antibodies and their uses
WO2007120368A2 (en) 2006-01-09 2007-10-25 The Regents Of The University Of California Immunostimulatory combinations for vaccine adjuvants
EP1981969A4 (en) 2006-01-19 2009-06-03 Genzyme Corp ANTI-GITRANT ANTIBODIES FOR THE TREATMENT OF CANCER
ES2523915T5 (es) 2006-12-01 2022-05-26 Seagen Inc Agentes de unión a la diana variantes y usos de los mismos
JP2008278814A (ja) 2007-05-11 2008-11-20 Igaku Seibutsugaku Kenkyusho:Kk アゴニスティック抗ヒトｇｉｔｒ抗体による免疫制御の解除とその応用
KR20080105674A (ko) 2007-05-31 2008-12-04 울산대학교 산학협력단 항-마우스 ｇｉｔｒｌ 단일클론 항체 또는 항-인간ａｉｔｒｌ 단일클론 항체 및 이를 유효성분으로 함유하는염증성 장질환의 예방 및 치료용 조성물
ES2591281T3 (es) 2007-07-12 2016-11-25 Gitr, Inc. Terapias de combinación que emplean moléculas de enlazamiento a GITR
HUE028958T2 (en) 2008-02-08 2017-01-30 Medimmune Llc Anti-IFNAR1 antibodies with reduced Fc ligand affinity
WO2009120922A2 (en) 2008-03-27 2009-10-01 Zymogenetics, Inc. Compositions and methods for inhibiting pdgfrbeta and vegf-a
PL3023438T3 (pl) 2009-09-03 2020-07-27 Merck Sharp & Dohme Corp. Przeciwciała anty-gitr
US10150808B2 (en) 2009-09-24 2018-12-11 Chugai Seiyaku Kabushiki Kaisha Modified antibody constant regions
EP2542590B2 (en) 2010-03-05 2020-04-01 The Johns Hopkins University Compositions and methods for targeted immunomodulatory antibodies and fusion proteins
JP2013528357A (ja) 2010-03-29 2013-07-11 ザイムワークス，インコーポレイテッド 強化又は抑制されたエフェクター機能を有する抗体
US8637641B2 (en) 2010-07-29 2014-01-28 Xencor, Inc. Antibodies with modified isoelectric points
CA2824278C (en) 2010-12-20 2022-09-20 The Rockefeller University Modulating agonistic tnfr antibodies
US20130323259A1 (en) 2011-01-17 2013-12-05 Novo Nordisk A/S Il-21 ligands
US9574002B2 (en) 2011-06-06 2017-02-21 Amgen Inc. Human antigen binding proteins that bind to a complex comprising β-Klotho and an FGF receptor
US20130108641A1 (en) 2011-09-14 2013-05-02 Sanofi Anti-gitr antibodies
WO2013043569A1 (en) 2011-09-20 2013-03-28 Vical Incorporated Synergistic anti-tumor efficacy using alloantigen combination immunotherapy
WO2013107413A1 (zh) * 2012-01-19 2013-07-25 中国科学院上海巴斯德研究所 磷酸化途径相关因子在调控调节性t细胞功能中的应用
TWI609882B (zh) 2012-05-22 2018-01-01 必治妥美雅史谷比公司 雙特異性抗體及其使用方法
KR101549637B1 (ko) 2012-06-08 2015-09-03 국립암센터 신규한 Ｔｈ1 세포 전환용 에피토프 및 이의 용도
CN104968364A (zh) 2012-12-03 2015-10-07 百时美施贵宝公司 强化免疫调变性Fc融合蛋白的抗癌活性
AR097306A1 (es) 2013-08-20 2016-03-02 Merck Sharp & Dohme Modulación de la inmunidad tumoral
TW201605896A (zh) * 2013-08-30 2016-02-16 安美基股份有限公司 Gitr抗原結合蛋白
CN107172880B (zh) 2014-03-24 2021-09-28 癌症研究技术有限公司 含有修饰IgG2结构域的引起激动或拮抗特性的修饰抗体及其用途
CN108064242B (zh) 2014-05-28 2022-10-21 阿吉纳斯公司 抗gitr抗体和其使用方法
HUE047385T2 (hu) * 2014-06-06 2020-04-28 Bristol Myers Squibb Co Antitestek glükokortikoid indukált tumornekrózis faktor receptor (GITR) ellen és annak felhasználásai
WO2016054638A1 (en) 2014-10-03 2016-04-07 Dana-Farber Cancer Institute, Inc. Glucocorticoid-induced tumor necrosis factor receptor (gitr) antibodies and methods of use thereof
WO2016196792A1 (en) 2015-06-03 2016-12-08 Bristol-Myers Squibb Company Anti-gitr antibodies for cancer diagnostics
WO2017087678A2 (en) 2015-11-19 2017-05-26 Bristol-Myers Squibb Company Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof
JP7274426B2 (ja) 2017-05-16 2023-05-16 ブリストル－マイヤーズ スクイブ カンパニー 抗ｇｉｔｒアゴニスト抗体での癌の処置

Also Published As

Publication number Publication date
MX2017015260A (es) 2018-02-19
CN107743586A (zh) 2018-02-27
US20180164321A1 (en) 2018-06-14
ES2810856T3 (es) 2021-03-09
EP3304079B1 (en) 2020-06-03
JP2018519508A (ja) 2018-07-19
CA2988115A1 (en) 2016-12-08
US10690674B2 (en) 2020-06-23
US20210011022A1 (en) 2021-01-14
EP3304079A1 (en) 2018-04-11
WO2016196792A1 (en) 2016-12-08
JP6812364B2 (ja) 2021-01-13
US11408889B2 (en) 2022-08-09
CN107743586B (zh) 2021-07-02
EA201792497A1 (ru) 2018-05-31

Similar Documents

Publication Publication Date Title
BR112017025297A2 (pt) anticorpos anti-gitr para diagnóstico do câncer
BR112019011186A2 (pt) conjugado de anticorpo radiomarcado, composto, e, métodos de imageamento e para tratamento de um tumor.
BR112017004773A2 (pt) biomarcadores para avaliar câncer de mama
EP4282405A3 (en) Detection of cancer biomarkers using nanoparticles
BR112014018331A8 (pt) Biomarcadores e terapias combinadas usando vírus oncolítico e imunomodulação
MX2020009021A (es) Ensayos para detectar la presencia o la cantidad de un anticuerpo antifarmaco.
BR122020006907B8 (pt) Anticorpo de domínio único anti-kras e seu uso, métodos in vitro para medir os níveis do referido anticorpo e para diagnosticar um distúrbio mediado por um componente intracelular, polipetídeo isolado e composição compreendendo o referido anticorpo ou polipeptídeo isolado
BR112015019614A8 (pt) análise de imagens e medições de amostras biológicas
EA201500835A1 (ru) Терапевтическая и диагностическая мишень для рака, включающая dll3-связывающие реагенты
BR112014031365A2 (pt) métodos de detectar doenças ou condições
BR112019010595A2 (pt) anticorpo ou fragmento de ligação ao antígeno do mesmo, combinação de moléculas de ácido nucleico isoladas, composição farmacêutica, kit, e, método para selecionar um composto.
BR112016003665A2 (pt) anticorpos e ensaios para detecção do receptor 1 de folato
BR112016002845A2 (pt) composições e métodos para tratar condições associadas ao complemento
BR112016029521A2 (pt) ?kit, dispositivo e método para a detecção de câncer de estômago?
MX2020000186A (es) Ensayos para evaluar los niveles de anticuerpos neutralizantes en sujetos tratados con un fármaco biológico y usos de los mismos en medicina personalizada.
CY1120063T1 (el) Αντισωματα κατα του ανθρωπινου dlk-1 που εχει δραση κατα των ογκων in vivo
MY195045A (en) Specific Biomarker Set For Non-Invasive Diagnosis of Liver Cancer
PE20180930A1 (es) Composiciones y metodos para la vigilancia activa del cancer de prostata
WO2016205828A3 (en) Role of citrullination in diagnosing diseases
BR112017022205A2 (pt) anticorpo anti-vegfr2 humano para terapia de câncer antiangiogênica e objetivada
BR112016017926A2 (pt) ensaio para detectar periostina humana
UY37082A (es) Anticuerpos monoclonales específicos para el antígeno piii de adenovirus humano (adv), producidos y secretados por hibridomas celulares, útiles para la detección y el diagnóstico de la infección causada por adv
BR112015027249A2 (pt) método de diagnóstico de câncer
NZ751193A (en) Protein biomarkers for diseases associated with the contact activation system
BR112019006422A2 (pt) anticorpo monoclonal contra fzd10 e utilização do mesmo

Legal Events

Date Code Title Description
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements
B350 Update of information on the portal [chapter 15.35 patent gazette]